Durham-based Bioventus, which sells orthobiologics for musculoskeletal conditions, postponed its planned initial public offering of stock, according to Renaissance Capital on its website.

It had filed to raise $150 million from 8.8 million shares priced between $16 and $18. It would have listed as BIOV on the Nasdaq exchange.

Founded in 2012, it had $266 million in sales in its last fiscal year, which ended in March.

Renaissance Capital: http://renaissancecapital.com/rencap/default.aspx

The story is also on Nasdaq.com: http://www.nasdaq.com/article/bioventus-postpones-150-million-ipo-cm657132